

2013

Applications for Pulse Power using Nanosecond Pulsed Electric Fields (nsPEFs) in Cell Biology and Cancer Treatment

Stephen J. Beebe

Old Dominion University, sbeebe@odu.edu

Follow this and additional works at: https://digitalcommons.odu.edu/bioelectrics_pubs

 Part of the [Cancer Biology Commons](#)

Repository Citation

Beebe, Stephen J., "Applications for Pulse Power using Nanosecond Pulsed Electric Fields (nsPEFs) in Cell Biology and Cancer Treatment" (2013). *Bioelectrics Publications*. 14.

https://digitalcommons.odu.edu/bioelectrics_pubs/14

Original Publication Citation

Beebe, S. J. (2013). Applications for pulse power using nanosecond pulsed electric fields (nspefs) in cell biology and cancer treatment. *J Nanomed Biotherapeut Discov*, 3, e123.

Applications for Pulse Power using Nanosecond Pulsed Electric Fields (nsPEFs) in Cell Biology and Cancer Treatment

Stephen J Beebe*

Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk VA, USA

Keywords: Apoptosis; Calcium mobilization; Mitochondria membrane potential; Electroporation; Basal cell carcinoma; Squamous cell carcinoma; Melanoma; Hepatocellular carcinoma; Pancreatic carcinoma

When engineers, physicists and molecular cell biologists began working together, pulse power technology evolved from uses in weaponry and high energy physics to applications in basic science and medicine, including cancer treatment. Pulse power technology uses capacitors with high voltage, fast discharge capabilities that serve as power pulse compression devices. The high voltage is released in nanoseconds into cancer cells or tumors, which are forced to respond to high power, low energy and non-thermal stimuli. Since nsPEFs do not exist in nature, eukaryotic cells evolved without such stimuli; therefore, it is of specific interest to determine how cells respond to these stimuli. As might be expected, responses to nsPEFs are distinct from those induced by previously known forms of cellular stresses [1].

A common example of the pulse power concept comes from storage of 1 joule (J) of energy and releasing it in extremely short times. Released in one second, one microsecond or one nanosecond, the peak power is one watt, one megawatt (one million watts, MW) or one gigawatt (a billion watts, GW), respectively. A one nanosecond pulse delivery yields 1.34 million horsepower. This is equivalent to the power of one of the three main shuttle rockets at lift off; however, it is delivered for just one nanosecond. How do tumor cells respond to this kind of power? This has been one of the focuses of the Frank Reidy Research Center for Bioelectrics and ten other Institutions that are presently part of the Bioelectrics Consortium, which began in 2005 by Old Dominion University in Norfolk, Virginia, Kumamoto University in Kumamoto, Japan and Institute for Pulsed Power and Microwave Technology at the Forschungszentrum Karlsruhe, Germany. So how are high pulse power physics and engineering developing new methods to treat cancer without chemotherapeutic cocktails, ionizing radiation, targeted small molecular weight inhibitors and neutralizing antibodies? However, this does not exclude possibilities that nsPEFs could be used in combination with these modalities [2].

Nanosecond pulsed electric fields charge membranes throughout the cell. One response is to form nanopores in plasma membranes and organelle membranes. Unlike conventional electroporation pores, nsPEFs generate large numbers of nanopores in all cell membranes—a phenomenon called supra-electroporation [3,4]. The presence of such nanopores was demonstrated experimentally as voltage-sensitive and inward-rectifying membrane pores [5]. There is emerging evidence that other structures may be directly and/or indirectly affected, such as enzymes and other proteins [6,7]. In any event, nsPEFs initiates distress signaling on a background of oncogenic signaling in cancer treatment. When electric fields are high enough, cell signaling leads to caspase-dependent apoptosis as well as caspase-independent mechanisms of cell death [8].

NsPEFs are delivered to cells between electrodes in cuvettes or on microscope slides and responses are analyzed such as changes in the mitochondria membrane potential by flow cytometry [9] or calcium

mobilization with fluorescent microscopy [10], respectively. For cancer treatment, pulses are delivered after surrounding tumors with needle, plate or suction electrodes. For complete clearance of tumors, it has been suggested that every tumor cell must receive a lethal threshold electric field. However, given a potential for an immune response, this recommendation may not be absolute, as will be presented below.

One interest over the last decade has been tumor elimination in several cancers that are readily approachable with external electrodes. These include melanoma [11,12], squamous cell carcinoma [13] and basal cell carcinoma [14,15]. NsPEFs have also been effective against hepatocellular carcinoma [16] and pancreatic carcinoma [17]. Treating these cancers will advance this technology to internal organs using laparoscopy and catheter electrodes.

Another interest understands what effects pulse waveform components have on cell structures. This is especially true for pulse fast rise and fall times, or in the frequency domain, high frequency components and what effects they have on plasma membranes versus intracellular structures such as mitochondria [9]. Results indicate that 600 ns pulses with fast rise-fall times (15 ns) have greater effects to decrease the mitochondria membrane potential ($\Delta\Psi_m$) and viability than slow rise-fall time (150 ns) pulses do. Under these conditions, extracellular calcium is necessary, but not sufficient for loss of $\Delta\Psi_m$ and cell death; influx of extracellular calcium and dissipation of $\Delta\Psi_m$ are both required for loss of cell viability.

Another perspective seeks to compare *in vitro* and *in vivo* efficacy and mechanisms of nsPEFs, especially for cell death and tumor clearance. In this comparison, a relationship holds constant for ectopic mouse B16f10 melanoma and ectopic Hepa1-6 HCC. When lethal conditions are compared by the product of pulse duration, electric field and pulse number, about a 30-fold greater product is required *in vivo* compared to *in vitro*. This relationship also holds true for orthotopic rat N1-S1 HCC cells and tumors. This should allow prediction of *in vivo* tumor-eliminating conditions from *in vitro* studies. Based on recent studies, cell death is induced, in part, by intrinsic apoptosis mechanisms *in vitro* [8] and *in vivo* [18].

A recently realized and exciting nsPEF property for effective cancer treatment is the possibility for an immune response after nsPEF treatment. Mice with successfully treated Hepa1-6 HCC tumors

*Corresponding author: Stephen J Beebe, Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk VA, USA, Tel: 757-683-2405; Fax: 757-451-1010; E-mail: sbeebe@odu.edu

Received April 16, 2013; Accepted April 18, 2013; Published April 20, 2013

Citation: Beebe SJ (2013) Applications for Pulse Power using Nanosecond Pulsed Electric Fields (nsPEFs) in Cell Biology and Cancer Treatment. J Nanomed Biotherapeut Discov 3: e123. doi:10.4172/2155-983X.1000e123

Copyright: © 2013 Beebe SJ. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

exhibited protection against a second challenge injection of the same tumor cells, while tumors were readily formed in naïve, aged-matched control mice [19]. Other evidence from UV-induced melanomas indicates that when mice treated with nsPEFs were compared to mice treated with tumor excision, the nsPEF-treated mice were superior at rejecting secondary tumor challenges. Also CD4⁺-T cells were present within treated tumors [20]. Additional evidence from an orthotopic N1-S1 HCC model also supports nsPEF-induced immune responses [21].

A major problem with advancing nsPEF technology is tight funding circumstances and proposing an unconventional treatment approach compared to individualized, targeted drug therapies. For nsPEFs, patient individualized treatments are not necessary; however presently, not all tumor types can be treated with nsPEFs. Most targeted and conventional cancer therapies, which require months of treatment, have only been temporarily successful before resistances occur. Cell death responses to nsPEFs appear to be much quicker, suggesting that changes for resistance developments should be lower. So far, all cancer cells and normal cells are susceptible when electric fields are sufficiently high. Then susceptible cells include cancer cells, host cells supporting tumor growth and cancer stem cells, which are not vulnerable to treatments that target rapidly dividing cells and may be responsible for some recurrences. In addition, providing further evidence for immune responses after nsPEF treatment should change perspective about this seemingly unconventional cancer treatment.

References

1. Morotomi-Yano K, Oyadomari S, Akiyama H, Yano K (2012) Nanosecond pulsed electric fields act as a novel cellular stress that induces translational suppression accompanied by eIF2 α phosphorylation and 4E-BP1 dephosphorylation. *Exp Cell Res* 318: 1733-1744.
2. Wang J, Guo J, Wu S, Feng H, Sun S, et al. (2012) Synergistic effects of nanosecond pulsed electric fields combined with low concentration of gemcitabine on human oral squamous cell carcinoma in vitro. *PLoS One* 7: e43213.
3. Stewart DA, Gowrishankar TR, Weaver JC (2004) Transport lattice approach to describing cell electroporation: use of a local asymptotic model. *IEEE Trans Plasma Sci* 32: 1696-1708.
4. Gowrishankar TR, Esser AT, Vasilkoski Z, Smith KC, Weaver JC (2006) Microdosimetry for conventional and supra-electroporation in cells with organelles. *Biochem Biophys Res Commun* 341: 1266-1276.
5. Pakhomov AG, Bowman AM, Ibey BL, Andre FM, Pakhomova ON, et al. (2009) Lipid nanopores can form a stable, ion channel-like conduction pathway in cell membrane. *Biochem Biophys Res Commun* 385: 181-186.
6. Morotomi-Yano K, Akiyama H, Yano K (2011) Nanosecond pulsed electric fields activate MAPK pathways in human cells. *Arch Biochem Biophys* 515: 99-106.
7. Beebe SJ, Sain NM, Ren W (2013) Induction of Cell Death Mechanisms and Apoptosis by Nanosecond Pulsed Electric Fields (nsPEFs). *Cells* 2: 136-162.
8. Ren W, Sain NM, Beebe SJ (2012) Nanosecond pulsed electric fields (nsPEFs) activate intrinsic caspase-dependent and caspase-independent cell death in Jurkat cells. *Biochem Biophys Res Commun* 421: 808-812.
9. Beebe SJ, Chen YJ, Sain NM, Schoenbach KH, Xiao S (2012) Transient features in nanosecond pulsed electric fields differentially modulate mitochondria and viability. *PLoS One* 7: e51349.
10. Semenov I, Xiao S, Pakhomov AG (2013) Primary pathways of intracellular Ca(2+) mobilization by nanosecond pulsed electric field. *Biochim Biophys Acta* 1828: 981-989.
11. Nuccitelli R, Pliquett U, Chen X, Ford W, Swanson JR, et al. (2006) Nanosecond pulsed electric fields cause melanomas to self-destruct. *Biochem Biophys Res Commun* 343: 351-360.
12. Chen X, Zhuang J, Kolb JF, Schoenbach KH, Beebe SJ (2012) Long term survival of mice with hepatocellular carcinoma after pulse power ablation with nanosecond pulsed electric fields. *Technol Cancer Res Treat* 11: 83-93.
13. Ren W, Beebe SJ (2011) An apoptosis targeted stimulus with nanosecond pulsed electric fields (nsPEFs) in E4 squamous cell carcinoma. *Apoptosis* 16: 382-393.
14. Garon EB, Sawcer D, Vernier PT, Tang T, Sun Y, et al. (2007) In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies. *Int J Cancer* 121:675-682.
15. Nuccitelli R, Huynh J, Lui K, Wood R, Kreis M, et al. (2012) Nano-electroablation of human pancreatic carcinoma in a murine xenograft model without recurrence. *Int J Cancer* 132: 1933-1939.
16. Chen X, Kolb JF, Swanson RJ, Schoenbach KH, Beebe SJ (2010) Apoptosis initiation and angiogenesis inhibition: melanoma targets for nanosecond pulsed electric fields. *Pigment Cell Melanoma Res* 23: 554-563.
17. Nuccitelli R, Tran K, Athos B, Kreis M, Nuccitelli P, et al. (2012) Nano-electroablation therapy for murine basal cell carcinoma. *Biochem Biophys Res Commun* 424: 446-450.
18. Vernier PT, Ziegler MJ, Sun Y, Gundersen MA, Tieleman DP (2006) Nanopore-facilitated, voltage-driven phosphatidylserine translocation in lipid bilayers—in cells and in silico. *Phys Biol* 3:233-247.
19. Beebe SJ, Ford WE, Ren W, Chen X (2011) Pulse Power Ablation of Melanoma with Nanosecond Pulsed Electric Fields, In: (Ed.) R. Morton, *Treatment of Metastatic Melanoma*. In Tech on Line, Croatia, 231-268.
20. Nuccitelli R, Tran K, Lui K, Huynh J, Athos B, et al. (2012) Non-thermal nano-electroablation of UV-induced murine melanomas stimulates an immune response. *Pigment Cell Melanoma Res* 25: 618-629.
21. Morotomi-Yano K, Uemura Y, Katsuki S, Akiyama H, Yano K (2011) Activation of the JNK pathway by nanosecond pulsed electric fields. *Biochem Biophys Res Commun* 408: 471-476.

Citation: Beebe SJ (2013) Applications for Pulse Power using Nanosecond Pulsed Electric Fields (nsPEFs) in Cell Biology and Cancer Treatment. *J Nanomed Biotherapeut Discov* 3: e123. doi:[10.4172/2155-983X.1000e123](https://doi.org/10.4172/2155-983X.1000e123)

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:

- 250 Open Access Journals
- 20,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: www.editorialmanager.com/pharma